Company intelligence / Profile preview

International Stem Cell Corporation

San Diego, California, United Statesinternationalstemcell.com ↗

Ownership: Public · ISCO
Development stage: Phase 1

Overview

Successfully completed Phase 1 clinical trial for Parkinson's disease treatment using ISC-hpNSC®. The therapy was found to be safe with no serious adverse effects related to the transplanted cells. Preliminary efficacy data showed potential dose-dependent response with middle dose showing peak effectiveness, with decreased OFF-time and increased ON-time without dyskinesia in Parkinson's patients.

Therapeutic areas: GastroenterologyRheumatologyNeurology
Modalities: Stem cell therapyCell-based therapies
Industry: Biotech

Drug pipeline

5 assets

ISC-hpNSC

4 more assets in the full pipeline.

Financials

Market cap: $1.2M
Total revenue: $9.1M
Enterprise value: $3.6M

Beyond the preview

Go deeper on International Stem Cell Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on International Stem Cell Corporation.